Chandra Bhagat Pharma Board of Directors
Get the latest insights into the leadership at Chandra Bhagat Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Hemant Chandravadan Bhagat | Chairman & Managing Director |
| Mr. Pranav Hemant Bhagat | Whole Time Director |
| Mrs. Prachi Pranav Bhagat | Director & CFO |
| Mr. Ravindra Gajanan Awati | Independent Director |
| Ms. Abha Praveen Doshi | Independent Director |
Chandra Bhagat Pharma Share price
CBPL
48.05
6.40 (-11.75%)Last updated on 3 Sep, 2025 | 13:27 IST
BUYSELL
Today's High
48.05
Today's Low
48.05
52 Week Low
46.15
52 Week High
85.50
The current prices are delayed, login to your account for live prices
LoginChandra Bhagat Pharma FAQs
The board at Chandra Bhagat Pharma consists of experienced professionals, including Mr. Hemant Chandravadan Bhagat , Mr. Pranav Hemant Bhagat , and others, overseeing the company’s strategic and corporate governance.
Directors at Chandra Bhagat Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Hemant Chandravadan Bhagat is the current chairman at Chandra Bhagat Pharma.
Executive directors at Chandra Bhagat Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Chandra Bhagat Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Chandra Bhagat Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.